Index Ventures made news recently when it announced a new €150 million fund to invest in early-stage, life science companies. With many venture firms scaling back or exiting the business entirely, any successful fundraising is good news. However, two aspects made the announcement from Index particularly noteworthy: first, the fund is focused on early-stage innovation, a segment largely shunned by traditional VCs and, second, two of the industry’s largest firms – Janssen and GlaxoSmithKline – agreed to throw their considerable weight behind the Index team.
To read the full, original article click on this link: Glaxo and J&J’s Shrewd Move Will Help the Biotech Ecosystem | Xconomy
